Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum

American Journal of Respiratory and Critical Care Medicine

Volumn 169, Issue 10, 2004, Pages 1110-1117

  Dent, Gordon ^a   Hadjicharalambous, Chrystalleni ^b   Yoshikawa, Takahiro ^b   Handy, Rachel L C ^b   Powell, John ^b   Anderson, Ian K ^b   Louis, Renaud ^b   Davies, Donna E ^b   Djukanovic, Ratko ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b NONE

Author keywords

Antibodies; Asthma; Chemokines; Chemotaxis

Indexed keywords

ANTIBODY CAT213; EOTAXIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHMA; BRONCHUS SECRETION; CELL ACTIVITY; CHEMOTAXIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHIL; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPUTUM ANALYSIS; SPUTUM CULTURE; T LYMPHOCYTE;

EID: 2442495483     PISSN: 00030805     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200306-855oc     Document Type: Article

References (38)

1. Jose PJ, Griffiths-Johnson DA, Collins PD, Walsh DT, Moqbel R, Totty NF, Truong O, Hsuan JJ, Williams TJ. Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation. J Exp Med 1994;179:881-887.
2. Conroy DM, Humbles AA, Rankin SM, Palframan RT, Collins PD, Griffiths-Johnson DA, Jose PJ, Williams TJ. The role of the eosinophil-selective chemokine, eotaxin, in allergic and non-allergic airways inflammation. Mem Inst Oswaldo Cruz 1997;92:183-191.
3. Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin Exp Immunol 1998;114:137-146.
4. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996;2:449-456.
5. Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD, Mackay CR. Chemokine receptor usage by human eosinophils: the importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J Clin Invest 1997;99:178-184.
6. Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 1997;277:2005-2007.
7. Uguccioni M, Mackay CR, Ochensberger B, Loetscher P, Rhis S, LaRosa GJ, Rao P, Ponath PD, Baggiolini M, Dahinden CA. High expression of the chemokine receptor CCR3 in human blood basophils: role in activation by eotaxin, MCP-4, and other chemokines. J Clin Invest 1997;100:1137-1143.
8. Lamkhioued B, Renzi PM, Abi-Younes S, Garcia-Zepada EA, Allakhverdi Z, Ghaffar O, Rothenberg MD, Luster AD, Hamid Q. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. J Immunol 1997;159:4593-4601.
9. Yamada H, Yamaguchi M, Yamamoto K, Nakajima T, Hirai K, Morita Y, Sano Y. Eotaxin in induced sputum of asthmatics: relationship with eosinophils and eosinophil cationic protein in sputum. Allergy 2000;55:392-397.
10. Nakamura H, Weiss ST, Israel E, Luster AD, Drazen JM, Lilly CM. Eotaxin and impaired lung function in asthma. Am J Respir Crit Care Med 1999;160:1952-1956.
11. Hirst SJ, Hallsworth MP, Peng Q, Lee TH. Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interieukin-1β and is mediated by the interleukin-4 receptor α-chain. Am J Respir Crit Care Med 2002;165:1161-1171.
12. Richter A, Puddicombe SM, Lordan JL, Bucchieri F, Wilson SJ, Djukanovic R, Dent G, Holgate ST, Davies DE. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Am J Respir Cell Mol Biol 2001;25:385-391.
13. Fujisawa T, Kato Y, Atsuta J, Terada A, Iguchi K, Kamiya H, Yamada H, Nakajima T, Miyamasu M, Hirai K. Chemokine production by the BEAS-2B human bronchial epithelial cells: differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines. J Allergy Clin Immunol 2000;105:126-133.
14. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, Garcia-Zepeda EA, Rothenberg ME, Drazen JM, Luster AD. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J Clin Invest 1997;99:1767-1773.
15. Mattoli S, Stacey MA, Sun G, Bellini A, Marini M. Eotaxin expression and eosinophilic inflammation in asthma. Biochem Biophys Res Commun 1997;236:299-301.
16. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-1721.
17. Jatakanon A, Lim S, Barnes PJ. Changes in sputum eosinophils predict loss of asthma control. Am J Respir Crit Care Med 2000;161:64-72.
18. Louis R, Shute J, Biagi S, Stanciu L, Marrelli F, Tenor H, Hidi R, Djukanovic R. Cell infiltration, ICAM-1 expression, and eosinophil chemotactic activity in asthmatic sputum. Am J Respir Crit Care Med 1997;155:466-472.
19. Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.
20. Polosa R, Louis R, Cacciola R, Prosperini G, Crimi N, Djukanovic R. Sputum eosinophilia is more closely associated with airway responsiveness to bradykinin than methacholine in asthma. Eur Respir J 1998;12:551-556.
21. May RD, Handy RLC, Main SH, Vaughan TJ, Anderson IK. In vitro and in vivo effects of CAT-213, a human anti-eotaxin monoclonal antibody [abstract]. Inflamm Res 2001;50:S188.
22. Dent G, Hadjicharalambous C, Ward J, Yoshikawa T, Angco G, Davies DE, Louis R, Handy RLC, Powell J, Anderson IK. CAT-213, an anti-eotaxin (CCL11) antibody, reveals a role for eotaxin in the eosinophil chemotactic activity of asthmatic sputum [abstract]. Thorax 2002;57 (Suppl III):19.
23. Dent G, Hadjicharalambous C, Louis R, Handy RL, Powell J, Anderson IK, Davies DE, Djukanovic R. Involvement of eotaxin (CCL11) in the eosinophil chemotactic activity of asthmatic sputum: effect of CAT-213, a human anti-eotaxin antibody [abstract]. Am J Respir Crit Care Med 2003;167:A758.
24. Hadjicharalambous C, Dent G, May RD, Handy RLC, Anderson IK, Davies DE, Djukanovic R. Measurement of eotaxin (CCL11) in induced sputum supernatants: validation and detection in asthma. J Allergy Clin Immunol 2004;113:657-662.
25. Dent G, Muñoz NM, Rühlmann E, Zhu X, Leff AR, Magnussen H, Rabe KF. Protein kinase C inhibition enhances platelet activating factor-induced eicosanoid production in human eosinophils. Am J Respir Cell Mol Biol 1998;18:136-144.
26. Taylor ML, Dastych J, Sehgal D, Sundstrom M, Nilsson G, Akin C, Mage RG, Metcalfe DD. The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis. Blood 2001;98:1195-1199.
27. Denholm EM, Stankus GP. Differential effects of two fluorescent probes on macrophage migration as assessed by manual and automated methods. Cytometry 1995;19:366-369.
28. Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma: association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 1997;27:3507-3516.
29. Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P, Djukanovic R. Analysis of fluid-phase mediators. Eur Respir J 2002;Suppl 37:24s-39s.
30. Gauvreau GM, Watson RM, O'Byrne PM. Kinetics of allergen-induced airway eosinophilic cytokine production and airway inflammation. Am J Respir Crit Care Med 1999;160:640-647.
31. Machold KP, Smolen JS. Adalimumab: a new TNF-α antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 2003;3:351-360.
32. Dent G. IgE modulation in asthma. Expert Opin Ther Patents 2003;13:1607-1617.
33. Brennan N, Case N, Meyers T, Amakye D, Doughty J, Forward JA, Varley P, Powell J, Glover DR. Pharmacokinetics of CAT-123, a human anti-eotaxin-1 monoclonal antibody, following single intravenous administration to healthy volunteers [abstract]. Br J Clin Pharmacol 2002;53:441P.
34. Pereira S, Clark T, Darby Y, Salib R, Salagean M, Hewitt L, Powell J, Howarth P, Scadding G. Effects of anti-eotaxin monoclonal antibody CAT-213 on allergen-induced rhinitis [abstract]. J Allergy Clin Immunol 2003;111:S268.
35. Salib R, Salagean M, Lau L, Di Giovanna I, Brennan N, Scadding G, Howarth P. The anti-inflammatory response of anti-eotaxin monoclonal antibody CAT-213 on nasal allergen-induced cell infiltration and activation [abstract]. J Allergy Clin Immunol 2003;111:S347.
36. Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Coanor BJ, Walls CM, Mathur AK, Cowley HC, Chung KF, Djukanovic R, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000;356:2144-2148.
37. Flood Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
38. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, Hein R, Smith T, Behrendt H, Ring J. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-2339.